GlaxoSmithKline
NEWS
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
The deal’s termination was announced Thursday, months after bintrafusp alfa failed to hit the mark in a Phase II clinical trial as a potential second-line treatment for metastatic biliary tract cancer.
GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company.
Moderna will leverage AbCellera’s AI-powered technology to search and analyze natural immune responses in the hopes of identifying antibodies for up to six targets.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
Replicate focuses on using self-replicating RNA (srRNA) to develop therapies for autoimmune and inflammatory diseases and prevent drug resistance in cancer.
The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate with patients having nasal polyps, and 52% in patients not having nasal polyps.
ZN-c3 is a WEE1 inhibitor that could be used as monotherapy for uterine serous carcinoma and solid tumors, as well as combination therapy for ovarian cancer, alongside chemotherapy.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
JOBS
IN THE PRESS